Future of GLP1s like Ozempic
About this video
Dr. Lyon discusses GLP-1 medications like Ozempic in the context of weight loss history, noting that while she describes these drugs as highly effective tools for weight reduction, she warns that a significant portion of weight lost may be lean muscle mass rather than fat. She argues that successful obesity treatment using GLP-1s must prioritize skeletal muscle health through resistance training and adequate protein intake, or users risk trading one health problem for another.
Key takeaways
- Dr. Lyon claims that up to 40% of weight lost on GLP-1 medications could be lean muscle mass rather than fat alone
- She argues that GLP-1 users who don’t engage in resistance training and consume adequate protein may be trading obesity for sarcopenia (muscle loss)
- Dr. Lyon advocates that future obesity medicine should focus on skeletal muscle health and measure success by strength gained rather than just pounds lost
Episode details: published June 16, 2025 · 23.7K views · 1:40 long. Summary written by Self Growth Videos from the episode itself. The health and muscle concepts described are Dr. Gabrielle Lyon’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices.
← Previous: Behind the Ozempic Shortage: The Science & Controversy Around Compounded GLP-1’s · Next: The #1 Organ Protecting You From Disease (It’s Not What You Think!) →
All Dr. Gabrielle Lyon videos · Dr. Gabrielle Lyon profile · Dr. Gabrielle Lyon on YouTube
You Might Also Enjoy

GLP-1 Side Effects, Risks, And Who Should Be Using It | Dr. Christle Guevarra | GLS #202
Explore →
GLP-1 Drugs Work… But Here’s the Catch
Explore →
The Truth About Testosterone in Women
Explore →
The Bone You Have At 50 Was Built Before You Turned 18
Explore →
The Coming Epidemic: Trading Obesity for Sarcopenia and Why Protein Is Our Only Defense
Explore →